AnteoTech (ADO) H1 2026 earnings summary

Executive summary

• Cost base structurally reset, with significant reductions in staff, contract, and director costs year-over-year, and streamlined operations to focus on sales conversion and strategic partnerships.

• Achieved technical and commercial milestones in both Advanced Battery Technologies and Life Sciences, including Ultranode® X reaching 1,020 cycles at 80% capacity retention, new product launches, and expanded customer evaluations.

• Raised AUD 3.5 million via capital raise, providing financial runway and supporting growth initiatives and strategic partnerships.

• Enhanced communication and targeted engagement with customers, supported by professional sales and marketing staff, and structured processes to drive sales performance.

• Secured a US$185,000 order from Serum Institute of India post-period and advanced joint development agreements.

Financial highlights

• Revenue and other income for H1 FY2026 was $2.7 million, down 15% year-over-year, mainly due to timing of Serum Institute orders; excluding SII, sales to other parties increased by 6%.

• Net loss after tax improved by 36% to $1,403,077 from $2,195,113 in the prior period, driven by cost-saving initiatives.

• Total expenses reduced by 24% year-over-year to $4.1 million, with a 31% reduction in staff costs and a 57% reduction in share-based payments.

• Cash on hand at period end was $1,443,040, with no debt and an additional $3.5 million raised post-period.

• R&D tax incentive refund received: $2,588,632.

Outlook and guidance

• Focus remains on converting the sales pipeline, securing new customers in both business units, and developing new diagnostic products.

• Well positioned for growth with recent capital raise, cash reserves, and contracted sales.

• Further cost-saving opportunities identified for the second half of the financial year.

• Anticipates continued growth in customer evaluations and product development collaborations, especially in CLIA and ELISA markets.

• No specific sales projections provided, but confidence expressed in ability to deliver.